Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Will Novo Nordisk's (NVO) Q2 Earnings Reflect Its Market Potential?

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

StockNews.com

These weight-loss startups tell customers they can stop taking Ozempic or Wegovy and stay thin. Doctors disagree

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

Fortune

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Weight Loss Drug Beats Ozempic In Head-to-head Study

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

International Business Times

Ozempic maker slams Biden after the president accused the drug company of ‘ripping off’ US consumers

Remarks came after the president and Senator Bernie Sanders blasted the pharmaceutical giant for its ‘unconscionably high prices’

The Independent UK

Weight-loss jabs may be linked to condition that can cause blindness, study finds

People with diabetes on semaglutide, found in Wegovy and Ozempic, four times more likely to be diagnosed with disease of optic nerve

The Guardian - UK

Ozempic weight loss drug linked to higher risk of eye condition that causes blindness

US study says patients could have higher risk of developing NAION

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Biden Calls For Lower Prices Of Ozempic, Similar Drugs

US President Joe Biden on Tuesday called on pharmaceutical giants Novo Nordisk and Eli Lilly to lower prices for diabetes and weight loss drugs such as Ozempic, saying firms must stop "ripping off the American people."

International Business Times

1 Huge New Reason This Diet Drug Stock is a Must-Own

The recent announcement that China approved Novo Nordisk's Wegovy is huge. Here's why: In a national survey conducted during 2015-2019 by China’s National Health Commission, more than half of the adult population was either overweight or obese. That's a massive market that just opened up for NVO.

Barchart

Novo Nordisk’s Wegovy may just have two years to take over China’s market for weight loss drugs

Novo Nordisk's China patent on Wegovy's active ingredient expires in 2026, much earlier than its patents in the U.S., Japan and Europe.

Fortune

‘Skinny jabs’: weight-loss drugs set for new boom as generic versions emerge

Alternatives to costly Wegovy and Saxenda will make such treatments more widely available worldwide

The Guardian - UK

Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand

Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy

The Guardian - UK

Sanders targets ‘unacceptable’ price of weight-loss drugs Ozempic and Wegovy

Vermont senator will grill CEO of Danish pharma giant whose drugs cost Americans 10 times more than abroad

The Guardian - US

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Kiplinger

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

WHO and Eli Lilly caution patients against falling for fake versions of popular weight-loss drugs

The World Health Organization and drugmaker Eli Lilly and Co. are warning patients to be wary of fake versions of weight-loss and diabetes medicines

The Conversation

Lawsuit could challenge trust in Ozempic and other popular weight loss drugs

The manufacturers of the most popular weight loss drugs are being challenged in court.

The Independent UK

Blaze at Danish drugmaker Novo Nordisk is the third in a little over a month

A fire has broken out at an office building belonging to Danish pharmaceutical company Novo Nordisk, the third in a little over a month to hit the drugmaker

Evening Standard

London women are falling pregnant on Ozempic — but no one knows if it's safe yet

As women in the UK are hit by the great ‘Ozempic pregnancy scare’ sweeping the US, fertility experts warn of its potential risks

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Novo Nordisk CEO to face off with Bernie Sanders over 1,300% Ozempic markup in U.S.

Novo's Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy's and Ozempic's eye-watering prices.

Al Jazeera

In China, weight-loss drugs are becoming big business

Chinese pharmaceutical companies are racing to roll out weight-loss drugs amid the popularity of Ozempic.

International Business Times UK

George Soros's Fund Sells Uber, Novo Nordisk in Q1 to Focus on AI, Construction, and Apparel Stocks

Soros Fund Management made several changes to its portfolio in Q1, increasing stakes in Alphabet, Nike, and D.R. Horton.

The Guardian - UK

Women advised to pair effective contraception with ‘skinny jabs’

Amid baby boom reports linked to drugs such as Wegovy and Ozempic, experts say it would be ‘wise’ to take extra precautions

StockNews.com

Eli Lilly (LLY) vs. Novo Nordisk (NVO): Which Pharma Stock Is Driving Long-Term 2024 Profits?

The pharmaceutical market is poised for rapid expansion due to rising global medical needs and increasing integration of technologies in drug discovery and development. Amid this, let’s analyze Eli Lilly (LLY) and Novo Nordisk (NVO) to determine which pharma stock will drive long-term profits in 2024. Read more to find…

Reason

It's Time for Over-the-Counter Ozempic

There's an easy way to lower the cost of next-generation weight-loss drugs.

Fortune

Nestlé is rolling out a new food brand just for Ozempic and Wegovy users

The company says its Vital Pursuit line, priced under $5, is high in protein and vitamins, addressing nutrient deficiencies that Ozempic and Wegovy users may have.

1 … 17 18 19 20

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.